Search Results for: Mesoblast

Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked

March 11, 2023 / By / 1 Comment
Victoria Gray, CRISPR meeting

Where do things stand with potential applications of CRISPR and other gene editing technologies in patients? Overall, things are looking very positive. CRISPR human trials This week the third big international human genome editing meeting took place in London. The summit addressed numerous potential clinical applications. It was good to see the agenda included quite …

Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked Read More »

Mesoblast stock hit on gloomy data on stem cells for COVID-19

June 7, 2022 / By / 3 Comments
mesoblast ceo dr silvio itescu

I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial …

Mesoblast stock hit on gloomy data on stem cells for COVID-19 Read More »

Weekend cell biology reads: Mesoblast COVID-19 deal, pubs

June 7, 2022 / By / 5 Comments
bergert cell stem cell 2020 cell mechanics sm

The COVID-19 pandemic is tearing through the country right as we are starting into the holiday season, but the wheels of science including cell biology keep going and we keep reading all the great work. What news or papers caught your eye? Here are some of the things I have on my list of reading. …

Weekend cell biology reads: Mesoblast COVID-19 deal, pubs Read More »

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval?

June 8, 2022 / By / 6 Comments
MSCs-mesenchymal-stem-cells-stromal-cells-small

Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow …

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval? Read More »

New Mesoblast “COVID kid” stem cell study

June 14, 2021 / By / 2 Comments
Dr-Fred-Grossman-CMO-Mesoblast.

The biotech Mesoblast is starting an expanded access study of its stem cell product for kids with a severe offshoot of COVID-19. The cellular drug in this case is remestemcel-L (more below). While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe …

New Mesoblast “COVID kid” stem cell study Read More »

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

February 1, 2021 / By / 3 Comments
EM-of-Novel-Coronavirus-SARS-CoV-2-that-causes-COVID-19

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an …

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »

Athersys & Mesoblast stem cells for COVID-19?

February 1, 2021 / By / 7 Comments
2019-nCoV-COVID-19-Pasteur

Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus disease COVID-19? Stem cells, ARDS, and COVID-19 I’ve already written two pieces about the idea of using stem cells to battle COVID-19 (here and here), the sometimes fatal disease that arises from infection with the novel coronavirus. Older patients …

Athersys & Mesoblast stem cells for COVID-19? Read More »

Mesoblast gets FDA RMAT; List of 10 total designations so far

August 23, 2022 / By / 13 Comments
Mesoblast-e1514313188176

Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting …

Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

February 1, 2021 / By / 2 Comments
VC-01-post-implant-final1-e1503703572933, viacyte

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

February 1, 2021 / By / 4 Comments
Mesoblast-stock

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner …

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »